Last reviewed · How we verify
AD-209-1B
AD-209-1B is a small molecule that targets the SGLT2 receptor.
AD-209-1B is a small molecule that targets the SGLT2 receptor. Used for Type 2 diabetes.
At a glance
| Generic name | AD-209-1B |
|---|---|
| Sponsor | Addpharma Inc. |
| Drug class | SGLT2 inhibitor |
| Target | SGLT2 |
| Modality | Small molecule |
| Therapeutic area | Diabetes |
| Phase | Phase 2 |
Mechanism of action
By inhibiting the SGLT2 receptor, AD-209-1B reduces glucose reabsorption in the kidneys, leading to increased glucose excretion in the urine and decreased blood glucose levels. This mechanism is thought to be beneficial for the treatment of type 2 diabetes.
Approved indications
- Type 2 diabetes
Common side effects
- Increased risk of genital mycotic infections
- Increased risk of urinary tract infections
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- AD-209-1B CI brief — competitive landscape report
- AD-209-1B updates RSS · CI watch RSS
- Addpharma Inc. portfolio CI